CA2501253A1 - Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments - Google Patents

Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments Download PDF

Info

Publication number
CA2501253A1
CA2501253A1 CA002501253A CA2501253A CA2501253A1 CA 2501253 A1 CA2501253 A1 CA 2501253A1 CA 002501253 A CA002501253 A CA 002501253A CA 2501253 A CA2501253 A CA 2501253A CA 2501253 A1 CA2501253 A1 CA 2501253A1
Authority
CA
Canada
Prior art keywords
drug
gene
act
variant allele
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002501253A
Other languages
English (en)
Inventor
Juergen Brockmoeller
Lorenz Truemper
Gerd Hasenfuss
Leszek Wojnowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA002501253A priority Critical patent/CA2501253A1/fr
Publication of CA2501253A1 publication Critical patent/CA2501253A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002501253A 2005-03-18 2005-03-18 Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments Abandoned CA2501253A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002501253A CA2501253A1 (fr) 2005-03-18 2005-03-18 Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002501253A CA2501253A1 (fr) 2005-03-18 2005-03-18 Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Publications (1)

Publication Number Publication Date
CA2501253A1 true CA2501253A1 (fr) 2006-09-18

Family

ID=37054271

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501253A Abandoned CA2501253A1 (fr) 2005-03-18 2005-03-18 Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments

Country Status (1)

Country Link
CA (1) CA2501253A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058394A1 (fr) * 2006-11-15 2008-05-22 The University Of British Columbia Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracycline
CN106987906A (zh) * 2017-05-15 2017-07-28 重庆市肿瘤研究所 肿瘤治疗心脏毒性预测基因突变检测文库的构建方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058394A1 (fr) * 2006-11-15 2008-05-22 The University Of British Columbia Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracycline
EP2312024A1 (fr) * 2006-11-15 2011-04-20 The University Of British Columbia Polymorphismes prédictifs de la cardiotoxicite induite par l'anthracyclin
EP2527501A1 (fr) * 2006-11-15 2012-11-28 The University Of British Columbia Polymorphismes prédictifs de la cardiotoxicité induite par l'anthracyclin
AU2007321678B2 (en) * 2006-11-15 2014-03-20 The University Of British Columbia Polymorphisms predictive of anthracycline-induced cardiotoxicity
CN106987906A (zh) * 2017-05-15 2017-07-28 重庆市肿瘤研究所 肿瘤治疗心脏毒性预测基因突变检测文库的构建方法

Similar Documents

Publication Publication Date Title
JP4516990B2 (ja) ワルファリンの投与量の範囲を予想する方法
EP1978107A1 (fr) Polymorphismes de gènes FTO associés à l'obésité et/ou les diabètes de type II
WO2006063704A2 (fr) Polymorphisme a simple nucleotide (snp)
US20070298426A1 (en) Warfarin dosage prediction
EP1673473A1 (fr) Utilisation de polymorphismes genetiques compatibles avec l'efficacite de traitement des maladies inflammatoires
EP1670954B1 (fr) Methodes d'evaluation de risques, de prevision de survie et de traitement de l'insuffisance cardiaque et d'autres etats pathologiques a partir de polymorphismes des recepteurs adrenergiques
US20040203034A1 (en) Optimization of cancer treatment with irinotecan
WO2006063703A2 (fr) Polymorphisme a simple nucleotide (snp)
CA2501253A1 (fr) Moyens et methodes de pharmacotherapie individuelle et de prevision des reactions indesirables aux medicaments
US6861217B1 (en) Variation in drug response related to polymorphisms in the β2-adrenergic receptor
US20030032099A1 (en) Methods for predicting susceptibility to obesity and obesity-associated health problems
US20100009366A1 (en) Polymorphisms in the human genes for oct1 and their use in diagnostic and therapeutic applications
US20090192135A1 (en) Human Niemann Pick C1-Like 1 Gene (NPC1L1) Polymorphisms and Methods of Use Thereof
US8236497B2 (en) Methods of diagnosing cardiovascular disease
ES2361018T3 (es) Uso de polimorfismos genéticos para predecir la hepatotoxicidad inducida por fármacos.
US7807350B2 (en) Methods for predicting irinotecan toxicity
JP5422805B2 (ja) 新規糖尿病性腎症感受性遺伝子
WO2011031769A2 (fr) Procédés pour l'évaluation des risques, le traitement, et le diagnostic d'un infarctus du myocarde
Ezzidi et al. Research article Common polymorphisms of calpain-10 and the risk of Type 2 Diabetes in a Tunisian Arab population: a case-control study
WO2006136791A1 (fr) Polymorphismes et haplotypes dans le gene p2x7 et utilisation de ceux-ci dans la determination de la susceptibilite a developper des maladies induites par l'atherosclerose

Legal Events

Date Code Title Description
FZDE Dead